Evotec AG operates as a drug discovery and development company that focuses on small molecule therapeutics for diseases in the areas of neuroscience, pain, and inflammation. Its product portfolio includes EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease, pain, and depression; EVT 201, a partial positive allosteric modulator of the GABAA receptor for the treatment of insomnia; EVT 302, a MAO-B inhibitor in development for smoking cessation; a P2X7 antagonist for the treatment of inflammatory diseases; and a small molecule vanilloid receptor antagonist for the treatment of pain. The company's proprietary late-stage preclinical research programs focuses on EVT 103, a back-up compound to EVT 101; H3 antagonists for the treatment of cognitive disorders and/or sleep, as well as antagonists for the purinergic receptor; and P2X3 for the treatment of pain. Evotec AG, through its research collaborations provide solutions that range from target to clinical development through a range of capabilities, including early-stage assay development and screening, fragment-based drug discovery, medicinal chemistry, and vivo pharmacology to the pharmaceutical and biotechnology industries. The company has collaborations with Boehringer Ingelheim, CHDI, Ono Pharmaceutical, and Novartis; and a strategic partnership with Roche for the development of compounds in treatment of resistant depression. Evotec AG, formerly known as EVOTEC BioSystems GmbH, was founded in 1993 and is headquartered in Hamburg, Germany.